Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamin… Read more
Beijing Tiantan Biological Products Corp Ltd (600161) - Total Assets
Latest total assets as of September 2025: CN¥16.55 Billion CNY
Based on the latest financial reports, Beijing Tiantan Biological Products Corp Ltd (600161) holds total assets worth CN¥16.55 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing Tiantan Biological Products Corp Ltd - Total Assets Trend (1995–2024)
This chart illustrates how Beijing Tiantan Biological Products Corp Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beijing Tiantan Biological Products Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing Tiantan Biological Products Corp Ltd's total assets of CN¥16.55 Billion consist of 48.7% current assets and 51.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.9% |
| Accounts Receivable | CN¥1.13 Billion | 7.2% |
| Inventory | CN¥3.87 Billion | 24.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.31 Billion | 8.2% |
| Goodwill | CN¥572.15 Million | 3.6% |
Asset Composition Trend (1995–2024)
This chart illustrates how Beijing Tiantan Biological Products Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Tiantan Biological Products Corp Ltd's current assets represent 48.7% of total assets in 2024, a decrease from 61.2% in 1995.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2024, down from 17.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is inventory at 24.4% of total assets.
Beijing Tiantan Biological Products Corp Ltd Competitors by Total Assets
Key competitors of Beijing Tiantan Biological Products Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Beijing Tiantan Biological Products Corp Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Beijing Tiantan Biological Products Corp Ltd generates 0.38x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Beijing Tiantan Biological Products Corp Ltd generates $9.76 in net profit.
Beijing Tiantan Biological Products Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.01 | 5.51 | 4.96 |
| Quick Ratio | 3.08 | 3.31 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.90 Billion | CN¥ 6.99 Billion | CN¥ 3.72 Billion |
Beijing Tiantan Biological Products Corp Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Tiantan Biological Products Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.85 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | CN¥15.87 Billion |
| Market Capitalization | $2.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Tiantan Biological Products Corp Ltd's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Beijing Tiantan Biological Products Corp Ltd's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Beijing Tiantan Biological Products Corp Ltd (1995–2024)
The table below shows the annual total assets of Beijing Tiantan Biological Products Corp Ltd from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥15.87 Billion | +11.85% |
| 2023-12-31 | CN¥14.19 Billion | +9.64% |
| 2022-12-31 | CN¥12.94 Billion | +11.77% |
| 2021-12-31 | CN¥11.58 Billion | +53.53% |
| 2020-12-31 | CN¥7.54 Billion | +19.43% |
| 2019-12-31 | CN¥6.31 Billion | +24.62% |
| 2018-12-31 | CN¥5.07 Billion | +38.22% |
| 2017-12-31 | CN¥3.67 Billion | -36.61% |
| 2016-12-31 | CN¥5.78 Billion | +2.69% |
| 2015-12-31 | CN¥5.63 Billion | -6.38% |
| 2014-12-31 | CN¥6.02 Billion | +6.76% |
| 2013-12-31 | CN¥5.63 Billion | +17.24% |
| 2012-12-31 | CN¥4.81 Billion | +49.07% |
| 2011-12-31 | CN¥3.22 Billion | +31.70% |
| 2010-12-31 | CN¥2.45 Billion | +13.28% |
| 2009-12-31 | CN¥2.16 Billion | +80.64% |
| 2008-12-31 | CN¥1.20 Billion | +9.26% |
| 2007-12-31 | CN¥1.09 Billion | +2.85% |
| 2006-12-31 | CN¥1.06 Billion | +25.42% |
| 2005-12-31 | CN¥848.76 Million | +11.31% |
| 2004-12-31 | CN¥762.49 Million | +0.47% |
| 2003-12-31 | CN¥758.95 Million | +50.36% |
| 2002-12-31 | CN¥504.77 Million | +8.95% |
| 2001-12-31 | CN¥463.32 Million | +3.89% |
| 2000-12-31 | CN¥445.98 Million | +1.46% |
| 1999-12-31 | CN¥439.55 Million | +16.18% |
| 1998-12-31 | CN¥378.34 Million | +140.60% |
| 1997-12-31 | CN¥157.25 Million | +18.01% |
| 1996-12-31 | CN¥133.25 Million | +6.73% |
| 1995-12-31 | CN¥124.85 Million | -- |